Prosigna^® - Breast Cancer Prognostic Gene Signature Assay

Prosigna^® is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.
Prosigna^® Breast Cancer Prognostic Gene Signature Assay for use on the Nanostring nCounter^® Dx Analysis System is 510(k) cleared and CE-marked for in vitro diagnostic use in the United States and EU, respectively. See Package Insert for details

Link to Prosigna^®